Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Abcuro, Inc.

Abcuro Announces Topline Results from the MUSCLE Study of Ulviprubart in Patients with Inclusion Body Myositis

February 24, 2026

From Abcuro, Inc.

Via Business Wire

Abcuro Presents Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting

December 08, 2025

From Abcuro, Inc.

Via Business Wire

Abcuro to Present Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting

November 03, 2025

From Abcuro, Inc.

Via Business Wire

Abcuro Appoints George Eldridge as Chief Financial Officer

August 18, 2025

From Abcuro, Inc.

Via Business Wire

Abcuro Appoints Courtney Cupples as Chief Commercial Officer

June 09, 2025

From Abcuro, Inc.

Via Business Wire

Abcuro to Present Two Posters at the American Academy of Neurology 2025 Annual Meeting

March 11, 2025

From Abcuro, Inc.

Via Business Wire

Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis

February 12, 2025

From Abcuro, Inc.

Via Business Wire

Abcuro Announces Participation in Upcoming Investor Conferences

November 11, 2024

From Abcuro, Inc.

Via Business Wire

Abcuro Announces Participation in Upcoming Investor Conferences

August 29, 2024

From Abcuro, Inc.

Via Business Wire

Abcuro Appoints Sarah Boyce to its Board of Directors

July 31, 2024

From Abcuro, Inc.

Via Business Wire

Abcuro Completes Enrollment of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart for the Treatment of Inclusion Body Myositis

June 25, 2024

From Abcuro, Inc.

Via Business Wire

Abcuro Appoints Mark Pruzanski, M.D., as Chairman of its Board of Directors

December 06, 2023

From Abcuro, Inc.

Via Business Wire

Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body Myositis

November 13, 2023

From Abcuro, Inc.

Via Business Wire

Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline

August 17, 2023

From Abcuro, Inc.

Via Business Wire

Abcuro Completes Enrollment of Sentinel Cohort in Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis

May 31, 2023

From Abcuro, Inc.

Via Business Wire

Abcuro Initiates Registrational Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis

April 03, 2023

From Abcuro, Inc.

Via Business Wire

Abcuro Initiates Phase 1/2 Trial Evaluating ABC008 in Patients with T Cell Large Granular Lymphocytic Leukemia

October 04, 2022

From Abcuro, Inc.

Via Business Wire

Abcuro to Present Late-Breaking Abstract at American College of Rheumatology Convergence 2021 of ABC008 Inclusion Body Myositis Phase 1 Data Demonstrating Proof of Mechanism for Selective Depletion of Highly Cytotoxic T Cells

November 05, 2021

From Abcuro, Inc.

Via Business Wire

Abcuro Appoints Darlene Deptula-Hicks to its Board of Directors

October 19, 2021

From Abcuro, Inc.

Via Business Wire

Abcuro to Present Trial in Progress Poster on a Phase 1 Clinical Trial of ABC008 Demonstrating Targeted Depletion of Large Granular Lymphocytes at the 2021 Leukemia, Lymphoma and Myeloma Congress

October 06, 2021

From Abcuro, Inc.

Via Business Wire

Abcuro and ImaginAb Share Initial Results of Study Using Novel Technology for Imaging T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis

June 30, 2021

From Abcuro, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.